<DOC>
	<DOCNO>NCT02820987</DOCNO>
	<brief_summary>This study evaluate PK/PD extended-infusion protocol meropenem , piperacillin-tazobactam cefepime , early phase septic shock .</brief_summary>
	<brief_title>PK/PD Extended-infusion Meropenem , Piperacillin-tazobactam Cefepime Early Phase Septic Shock</brief_title>
	<detailed_description>Beta Lactams keystone shock septic treatment . Early phase septic shock period disturb pharmacokinetics , augment renal clearance distribution volume hydrophilic drug Beta Lactams . Consequently , early phase septic shock period risk underdosing Beta Lactam , could increase risk clinical failure mortality . Data available concern underdosing MEROPENEM , PIPERACILLIN-TAZOBACTAM CEFEPIME , administer bolus . No data exist concern achievement target 100 % whole interval 4 time superior breakpoint Pseudomonas Aeruginosa accord EUCAST ( European Committee Antimicrobial Susceptibility Testing ) , 48 first hour treatment septic shock , Beta Lactam administer extended infusion .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<mesh_term>Cefepime</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Septic shock Meropenem , piperacillintazobactam cefepime start enrollment Pregnancy Central nervous system infection Burns</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Septic shock , Beta Lactams , Extended infusion , PK/PD</keyword>
</DOC>